These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16956818)

  • 1. Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial.
    Voskaridou E; Anagnostopoulos A; Konstantopoulos K; Stoupa E; Spyropoulou E; Kiamouris C; Terpos E
    Haematologica; 2006 Sep; 91(9):1193-202. PubMed ID: 16956818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia.
    Perifanis V; Vyzantiadis T; Tziomalos K; Vakalopoulou S; Garipidou V; Athanassiou-Metaxa M; Harsoulis F
    Ann Hematol; 2007 Jan; 86(1):23-30. PubMed ID: 17013645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial.
    Otrock ZK; Azar ST; Shamseddeen WA; Habr D; Inati A; Koussa S; Mahfouz RA; Taher AT
    Ann Hematol; 2006 Sep; 85(9):605-9. PubMed ID: 16830143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia.
    Voskaridou E; Terpos E; Spina G; Palermos J; Rahemtulla A; Loutradi A; Loukopoulos D
    Br J Haematol; 2003 Nov; 123(4):730-7. PubMed ID: 14616979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates in the treatment of thalassemia-induced osteoporosis.
    Morabito N; Lasco A; Gaudio A; Crisafulli A; Di Pietro C; Meo A; Frisina N
    Osteoporos Int; 2002 Aug; 13(8):644-9. PubMed ID: 12181623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia.
    Gilfillan CP; Strauss BJ; Rodda CP; Bowden DK; Kean AM; Obaid M; Crawford BA
    Calcif Tissue Int; 2006 Sep; 79(3):138-44. PubMed ID: 16969592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
    Israeli RS; Rosenberg SJ; Saltzstein DR; Gottesman JE; Goldstein HR; Hull GW; Tran DN; Warsi GM; Lacerna LV
    Clin Genitourin Cancer; 2007 Mar; 5(4):271-7. PubMed ID: 17553207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent zoledronic Acid prevents bone loss in adults after allogeneic hematopoietic cell transplantation.
    Hari P; DeFor TE; Vesole DH; Bredeson CN; Burns LJ
    Biol Blood Marrow Transplant; 2013 Sep; 19(9):1361-7. PubMed ID: 23806773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of Intravenous Zoledronic Acid Every 3 Months vs. Annually in β-thalassemia Patients with Low Bone Mineral Density: a Retrospective Comparison of Efficacy.
    Darvishi-Khezri H; Kosaryan M; Akbarzadeh R; Aliasgharian A; Fazli M
    Med Arch; 2018 Jun; 72(3):170-173. PubMed ID: 30061760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
    J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers.
    Trovas GP; Lyritis GP; Galanos A; Raptou P; Constantelou E
    J Bone Miner Res; 2002 Mar; 17(3):521-7. PubMed ID: 11874243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
    Reid IR; Brown JP; Burckhardt P; Horowitz Z; Richardson P; Trechsel U; Widmer A; Devogelaer JP; Kaufman JM; Jaeger P; Body JJ; Brandi ML; Broell J; Di Micco R; Genazzani AR; Felsenberg D; Happ J; Hooper MJ; Ittner J; Leb G; Mallmin H; Murray T; Ortolani S; Rubinacci A; Saaf M; Samsioe G; Verbruggen L; Meunier PJ
    N Engl J Med; 2002 Feb; 346(9):653-61. PubMed ID: 11870242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration.
    Voskaridou E; Christoulas D; Xirakia C; Varvagiannis K; Boutsikas G; Bilalis A; Kastritis E; Papatheodorou A; Terpos E
    Haematologica; 2009 May; 94(5):725-8. PubMed ID: 19407319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
    Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone turnover 18 months after a single intravenous dose of zoledronic acid.
    Borba VZ; Paz-Filho G; Kulak CA; Seibel MJ; Bilezikian JP
    Int J Clin Pract; 2007 Jun; 61(6):1058-62. PubMed ID: 17504370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial.
    Voskaridou E; Ntanasis-Stathopoulos I; Papaefstathiou A; Christoulas D; Dimopoulou M; Repa K; Papatheodorou A; Peppa M; Terpos E
    Blood Adv; 2018 Nov; 2(21):2837-2847. PubMed ID: 30381400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone turnover and periprosthetic bone loss after cementless total hip arthroplasty can be restored by zoledronic acid: a prospective, randomized, open-label, controlled trial.
    Huang TW; Wang CJ; Shih HN; Chang Y; Huang KC; Peng KT; Lee MS
    BMC Musculoskelet Disord; 2017 May; 18(1):209. PubMed ID: 28532408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis.
    Morabito N; Catalano A; Gaudio A; Morini E; Bruno LM; Basile G; Tsiantouli E; Bellone F; Agostino RM; Piraino B; La Rosa MA; Salpietro C; Lasco A
    J Bone Miner Metab; 2016 Sep; 34(5):540-6. PubMed ID: 26204844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.